BamSEC and AlphaSense Join Forces
Learn More

Roivant Sciences Ltd. – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: ROIV    
Share price (8/21/26): $36.30    
Market cap (8/21/26): $26.2 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 153 pages Certain Information Has Been Redacted From His Exhibit in Accordance With Item 601(b)(10)(iv) of Regulation S-K Because Such Information (I) Is Not Material and (II) Is the Type of Information the Registrant Treats as Private or Confidential. Information That Has Been So Redacted From This Exhibit Has Been Marked With “[***]” to Indicate the Omission
12/34/56
EX-2.1
from 10-Q 101 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Roivant Sciences Ltd. (The “Company”) Has Determined That the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed
12/34/56
EX-2.9
from 10-K 3 pages Amendment No. 1 to Business Combination Agreement
12/34/56
EX-2.1
from 10-K 106 pages Business Combination Agreement by and Among Montes Archimedes Acquisition Corp., Rhine Merger Sub, Inc., and Roivant Sciences Ltd. Dated as of May 1, 2021
12/34/56
EX-2.4
from S-4/A 6 pages Amendment No. 1 to Stock Purchase Agreement
12/34/56
EX-2.3
from S-4/A 116 pages Stock Purchase Agreement by and Among Oncopia Therapeutics, Inc. (The “Company”), Pharmavant 5, Inc. (“Purchaser”), the Selling Securityholders Named Herein (“Selling Securityholders”) and [***] (As “Seller Representative”) Dated as of November 6, 2020
12/34/56
EX-2.2
from S-4/A 136 pages Agreement and Plan of Merger Dated as of February 2, 2021 by and Among Roivant Sciences Ltd., Silicon Insite, Inc., Silicon Tx China and Silicon Therapeutics, LLC
12/34/56
EX-2.8
from S-4 3 pages Amendment Number One to Asset Purchase Agreement
12/34/56
EX-2.7
from S-4 107 pages Asset Purchase Agreement
12/34/56
EX-2.6
from S-4 85 pages Asset Purchase Agreement by and Among Glaxosmithkline Intellectual Property Development Ltd., Glaxo Group Limited, and Dermavant Sciences Gmbh July 10, 2018
12/34/56